KITS Eyecare (KITS) fell 8% on its preliminary Q3 results, which were strong at 25% Y/Y revenue growth…

… and 5% adj. EBITDA margins, as the operating leverage inherent in KITS’ business model starts to show with scale.

With the stock doubling this year, investors were likely looking for a big beat - feels like a breather rather than a change in the thesis.